Bleeding Disorders Treatment Market Size was valued at USD 23.76 Billion in 2023. The Global Bleeding Disorders Treatment industry is projected to grow from USD 24.81 Billion in 2024 to USD 30.31 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.76% during the forecast period (2024 - 2032).
A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own.
Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.
In April 2024, a copy of DDAVP (desmopressin acetate), a drug used to treat mild hemophilia A that was approved by the F.D.A. as an agent for controlling bleeding episodes in mild hemophilia A patients, is now available in the U.S.A. According to its press release, Avenacy planned to commence shipment the week commencing from April 15. The generic form is referred to as Desmopressin Acetate for Injection and can be bought from this page. It comes as single-dose vials with four mcg/mL or multiple-dose vials with 40 mcg/10 mL. Just like the brand-name drug itself, the generic medication is administered through IV (intravenous) or subcutaneous injection.
Pfizer announced on Wednesday that Canada’s health regulator had given its gene therapy for the treatment of hemophilia B a go-ahead before the U.S. decision, making it potentially the first such treatment on the market in North America. In its release, Pfizer noted that the approval was based on phase III trials showing that it outperformed the current standard of care, which involves the replacement of factor IX and will be marketed under the Beqvez brand name, but Hemlibra will remain a competitor according to analyst opinion. The targets are people over 18 years old who have moderately severe and severe hemophilia B.CSL’s Hemgenix became an FDA-approved pharmaceutical company in November 2022, consequently becoming the first ever one-time gene therapy approved by U.S.A.’s Food and Drug Administration (F.D.A.) for patients with hemophilia B.
In December 2023, Hemab Therapeutics announced the completion of the single ascending dose part of Phase 1 and transition to the multiple ascending dose part (Phase 2) of its Phase I/II clinical study in Glanzmann Thrombasthenia (G.T.), a rare, potentially life-threatening platelet disorder that causes severe bleeding. In addition, Hemab reported regulatory clearance by the F.D.A. for its investigational new drug application (HMB-001) in G.T., thereby allowing enrolment into phase I trial in the U.S. Phase 1 was conducted in the U.K. while Phase 2 will involve additional sites across Europe and U.S.A.
The bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market.
The bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users.
On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others.
On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market.
On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials).
On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD).
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia.
The market in the Middle East & Africa is expected to account for the smallest share of the bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Some of the key players in the bleeding disorders treatment market are:
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USD 30.31 Billion (By 2032) |
| Â Â CAGR | Â Â 10.76% |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2022 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Drug class, Treatment and End users |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
| Â Â Key Market Drivers | Growth in the number of diagnosed patients with bleeding disorders Rising research and development activities Growth in awareness about bleeding disorders |
Frequently Asked Questions (FAQ) :
The bleeding disorders treatment market is projected to grow at a 10.76% CAGR between 2024-2032.
North America is projected to command the largest share in the bleeding disorders treatment market.
End users of bleeding disorders treatment market include specialty clinics, hospitals, clinics, and others.
Favorable compensation policies and increasing awareness may limit market growth.
High medication costs may limit market growth.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
